A single, low dose of a cGMP recombinant BCG vaccine elicits protective T cell immunity against the human respiratory syncytial virus infection and prevents lung pathology in mice
A single dose of 3 × 105 CFUs of rBCG-N-hRSV cGMP elicits T-cell memory against hRSV. rBCG-N-hRSV cGMP elicits a strong antiviral TH1/TH17 T-cell repertoire. Vaccination prevents viral pneumonia and CNS-alterations associated with hRSV. rBCG-N-hRSV cGMP elicits a strong anti-mycobacterial TH1/TH17 T-cell repertoire. Immunity to hRSV and Mtb antigens develops without observable adverse effects.